AM–Pharma is a biopharmaceutical company developing novel recombinant human alkaline phosphatase therapeutics, which have the potential to transform the treatment prospects for patients with chronic or life-threatening inflammatory diseases.
Disease modifying therapies
AM-Pharma discovered that alkaline phosphatase can protect organs against inflammation and tissue damage. While this enzyme is found in many cells of the body, it is present at reduced levels in certain diseases including Acute Kidney Injury and Ulcerative Colitis.
The Company’s proprietary therapeutics are disease modifying therapies and have the potential to be “first-in-class” medicines.
Lead programs and partnering
AM-Pharma will be seeking partnerships for its lead programs in Acute Kidney Injury and Inflammatory Bowel Disease.
Acute Kidney Injury is an acute inflammation of the kidney, which results in kidney damage and a rapid loss of kidney function and often leads to dialysis. There are currently no approved drugs for disease treatment.
Inflammatory Bowel Disease is a group of inflammatory conditions of the colon and small intestine. The major types include Crohn's disease and Ulcerative Colitis. There is only one biologic (an injectable) approved for treating ulcerative colitis, which means that as an oral therapy, AM Pharma’s alkaline phosphatase has convincing potential benefits.